Duration and extent of antianginal effects of a sustained-release formulation of nifedipine in angina

M. Yokota, F. Saito, Hideo Izawa, T. Matsunami, J. Yoshida, H. Inagaki, I. Sotobata

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Twenty-four patients with chronic stable exertional angina pectoris were randomized in a double-blind, placebo-controlled, crossover trial to assess the efficacy and durability of a newly developed sustained-release formulation of nifedipine (nifedipine CC) in a single 40-mg oral dose. Symptom-limited graded treadmill exercise tests were performed just before and at 4, 7, and 24 h after a single administration of the drug or the placebo was given. Exercise tolerance at 4, 7, and 24 h after the drug were compared with the corresponding placebo values. Data could be analysed for 19 patients. Maximal exercise time time to the onset of angina and time to 1 mm ST segment depression were significantly greater at 4, 7, and 24 h after nifedipine CC than at baseline or with the corresponding placebo. The average maximal exercise time was significantly increased by 72, 76 and 37 s at 4, 7, and 24 h. Rate-pressure product at rest and at peak exercise showed significant changes only at 24 h compared with placebo (both P < 0.05). The maximal increase in exercise tolerance was most marked at 7 h after nifedipine CC at which time plasma drug concentration was 99.4 ± 14.0 ng.ml -1 . Thus, in patients with chronic stable exertional angina pectoris nifedipine CC showed a prolonged improvement in exercise tolerance up to 24 h after a single oral administration.

Original languageEnglish
Pages (from-to)965-970
Number of pages6
JournalEuropean Heart Journal
Volume15
Issue number7
DOIs
Publication statusPublished - 01-01-1994
Externally publishedYes

Fingerprint

Nifedipine
Stable Angina
Placebos
Exercise Tolerance
Exercise
Exercise Test
Pharmaceutical Preparations
Cross-Over Studies
Oral Administration
Pressure

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Yokota, M. ; Saito, F. ; Izawa, Hideo ; Matsunami, T. ; Yoshida, J. ; Inagaki, H. ; Sotobata, I. / Duration and extent of antianginal effects of a sustained-release formulation of nifedipine in angina. In: European Heart Journal. 1994 ; Vol. 15, No. 7. pp. 965-970.
@article{842f8dc6fe0940daa63f2c05edab1e7a,
title = "Duration and extent of antianginal effects of a sustained-release formulation of nifedipine in angina",
abstract = "Twenty-four patients with chronic stable exertional angina pectoris were randomized in a double-blind, placebo-controlled, crossover trial to assess the efficacy and durability of a newly developed sustained-release formulation of nifedipine (nifedipine CC) in a single 40-mg oral dose. Symptom-limited graded treadmill exercise tests were performed just before and at 4, 7, and 24 h after a single administration of the drug or the placebo was given. Exercise tolerance at 4, 7, and 24 h after the drug were compared with the corresponding placebo values. Data could be analysed for 19 patients. Maximal exercise time time to the onset of angina and time to 1 mm ST segment depression were significantly greater at 4, 7, and 24 h after nifedipine CC than at baseline or with the corresponding placebo. The average maximal exercise time was significantly increased by 72, 76 and 37 s at 4, 7, and 24 h. Rate-pressure product at rest and at peak exercise showed significant changes only at 24 h compared with placebo (both P < 0.05). The maximal increase in exercise tolerance was most marked at 7 h after nifedipine CC at which time plasma drug concentration was 99.4 ± 14.0 ng.ml -1 . Thus, in patients with chronic stable exertional angina pectoris nifedipine CC showed a prolonged improvement in exercise tolerance up to 24 h after a single oral administration.",
author = "M. Yokota and F. Saito and Hideo Izawa and T. Matsunami and J. Yoshida and H. Inagaki and I. Sotobata",
year = "1994",
month = "1",
day = "1",
doi = "10.1093/oxfordjournals.eurheartj.a060617",
language = "English",
volume = "15",
pages = "965--970",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "7",

}

Duration and extent of antianginal effects of a sustained-release formulation of nifedipine in angina. / Yokota, M.; Saito, F.; Izawa, Hideo; Matsunami, T.; Yoshida, J.; Inagaki, H.; Sotobata, I.

In: European Heart Journal, Vol. 15, No. 7, 01.01.1994, p. 965-970.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Duration and extent of antianginal effects of a sustained-release formulation of nifedipine in angina

AU - Yokota, M.

AU - Saito, F.

AU - Izawa, Hideo

AU - Matsunami, T.

AU - Yoshida, J.

AU - Inagaki, H.

AU - Sotobata, I.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Twenty-four patients with chronic stable exertional angina pectoris were randomized in a double-blind, placebo-controlled, crossover trial to assess the efficacy and durability of a newly developed sustained-release formulation of nifedipine (nifedipine CC) in a single 40-mg oral dose. Symptom-limited graded treadmill exercise tests were performed just before and at 4, 7, and 24 h after a single administration of the drug or the placebo was given. Exercise tolerance at 4, 7, and 24 h after the drug were compared with the corresponding placebo values. Data could be analysed for 19 patients. Maximal exercise time time to the onset of angina and time to 1 mm ST segment depression were significantly greater at 4, 7, and 24 h after nifedipine CC than at baseline or with the corresponding placebo. The average maximal exercise time was significantly increased by 72, 76 and 37 s at 4, 7, and 24 h. Rate-pressure product at rest and at peak exercise showed significant changes only at 24 h compared with placebo (both P < 0.05). The maximal increase in exercise tolerance was most marked at 7 h after nifedipine CC at which time plasma drug concentration was 99.4 ± 14.0 ng.ml -1 . Thus, in patients with chronic stable exertional angina pectoris nifedipine CC showed a prolonged improvement in exercise tolerance up to 24 h after a single oral administration.

AB - Twenty-four patients with chronic stable exertional angina pectoris were randomized in a double-blind, placebo-controlled, crossover trial to assess the efficacy and durability of a newly developed sustained-release formulation of nifedipine (nifedipine CC) in a single 40-mg oral dose. Symptom-limited graded treadmill exercise tests were performed just before and at 4, 7, and 24 h after a single administration of the drug or the placebo was given. Exercise tolerance at 4, 7, and 24 h after the drug were compared with the corresponding placebo values. Data could be analysed for 19 patients. Maximal exercise time time to the onset of angina and time to 1 mm ST segment depression were significantly greater at 4, 7, and 24 h after nifedipine CC than at baseline or with the corresponding placebo. The average maximal exercise time was significantly increased by 72, 76 and 37 s at 4, 7, and 24 h. Rate-pressure product at rest and at peak exercise showed significant changes only at 24 h compared with placebo (both P < 0.05). The maximal increase in exercise tolerance was most marked at 7 h after nifedipine CC at which time plasma drug concentration was 99.4 ± 14.0 ng.ml -1 . Thus, in patients with chronic stable exertional angina pectoris nifedipine CC showed a prolonged improvement in exercise tolerance up to 24 h after a single oral administration.

UR - http://www.scopus.com/inward/record.url?scp=0028240873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028240873&partnerID=8YFLogxK

U2 - 10.1093/oxfordjournals.eurheartj.a060617

DO - 10.1093/oxfordjournals.eurheartj.a060617

M3 - Article

VL - 15

SP - 965

EP - 970

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 7

ER -